Vertex Pharmaceuticals Announces Conditional Marketing Authorization Granted By European Commission For CASGEVY™, A CRISPR/Cas9 Gene-Edited Therapy
Portfolio Pulse from Benzinga Newsdesk
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has received conditional marketing authorization from the European Commission for CASGEVY™, a CRISPR/Cas9 gene-edited therapy for severe sickle cell disease and transfusion-dependent beta thalassemia in patients 12 years and older. This makes CASGEVY the only genetic therapy approved for these conditions in the EU, potentially benefiting over 8,000 patients.
February 13, 2024 | 7:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals' CASGEVY™ receives conditional marketing authorization from the European Commission for treating severe sickle cell disease and transfusion-dependent beta thalassemia, marking it as the only approved genetic therapy for these conditions in the EU.
The conditional marketing authorization of CASGEVY™ by the European Commission is a significant milestone for Vertex Pharmaceuticals, as it opens up a new treatment avenue for over 8,000 patients in the EU with severe sickle cell disease and transfusion-dependent beta thalassemia. This approval not only enhances the company's product portfolio but also strengthens its position in the genetic therapy market. The exclusivity as the only approved genetic therapy for these conditions in the EU is likely to have a positive impact on Vertex's stock price in the short term, given the potential market size and the groundbreaking nature of the therapy.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100